Journal of Obesity & Metabolic Syndrome最新文献_第8页

A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus. 一种新的人体测量参数，体重调整腰围指数代表新诊断的2型糖尿病的肌肉减少性肥胖。

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-06-30 DOI: 10.7570/jomes23005

Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo

{"title":"A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus.","authors":"Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo","doi":"10.7570/jomes23005","DOIUrl":"https://doi.org/10.7570/jomes23005","url":null,"abstract":"Background: As the metabolic significance of sarcopenic obesity (SO) is revealed, finding an appropriate index to detect SO is important, especially for type 2 diabetes mellitus (T2DM) patients with accompanying metabolic dysfunction.Methods: Participants (n=515) from the Korea Guro Diabetes Program were included to compare how well waist circumference (WC), waist hip ratio (WHR), waist height ratio (WHtR), and the weight-adjusted waist index (WWI) predict SO in newly diagnosed T2DM patients. Sarcopenia was defined based on guidelines from the 2019 Asian Working Group for Sarcopenia as both low muscle mass (appendicular skeletal muscle [ASM]/height2 <7.0 kg/m2 for men, <5.4 kg/m2 for women) and strength (handgrip strength <28.0 kg for men, <18.0 kg for women) and/or reduced physical performance (gait speed <1.0 m/sec). Obesity was defined as a WC ≥90 cm in men and ≥85 cm in women. The WHR, WHtR, and WWI were calculated by dividing the WC by the hip circumference, height, and √ weight, respectively.Results: The WC, WHR, and WHtR correlated positively with the fat and muscle mass represented by truncal fat amount (TFA) and ASM, whereas the WWI was proportional to the TFA and inversely related to ASM. Of the four indices, the WWI showed the highest area under the receiver operative characteristic curve for SO. The WWI also exhibited a positive correlation with albuminuria and the mean brachial-ankle pulse wave velocity, especially in patients aged ≥65 years.Conclusion: The WWI is the preferable anthropometric index for predicting SO in T2DM patients, and it might be a proper index for predicting cardiometabolic risk factors in elderly people.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"130-140"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/31/jomes-32-2-130.PMC10327688.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9751926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Temporal Trends of the Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents between 2007 and 2020. 2007年至2020年韩国儿童和青少年腹部肥胖和代谢综合征患病率的时间趋势

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-06-30 DOI: 10.7570/jomes22059

Jieun Lee, Sung-Chan Kang, Obin Kwon, Seung-Sik Hwang, Jin Soo Moon, Hyun Wook Chae, Jaehyun Kim

{"title":"Temporal Trends of the Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents between 2007 and 2020.","authors":"Jieun Lee, Sung-Chan Kang, Obin Kwon, Seung-Sik Hwang, Jin Soo Moon, Hyun Wook Chae, Jaehyun Kim","doi":"10.7570/jomes22059","DOIUrl":"https://doi.org/10.7570/jomes22059","url":null,"abstract":"Background: The prevalence of obesity in children and adolescents is increasing worldwide, which is of concern because obesity can lead to various complications such as metabolic syndrome (MS). Waist circumference (WC) and waist-height ratio (WHtR) are useful indicators of abdominal obesity and MS. In this study, we investigate trends in the prevalence of abdominal obesity and MS using two different references.Methods: Data from the Korea National Health and Nutrition Examination Survey (2007 to 2020) were used. In total, 21,652 participants aged 2 to 18 years and 9,592 participants aged 10 to 18 years were analyzed for abdominal obesity and MS, respectively. The prevalence of abdominal obesity and that of MS were compared using the Korean National Growth Chart in 2007 (REF2007) and the newly published WC and WHtR reference values in 2022 (REF2022).Results: Both WC and WHtR showed an increasing trend. The prevalence of abdominal obesity was 14.71% based on REF2022, 5.85% points higher than that of 8.86% based on REF2007. MS based on REF2022 had a higher prevalence for both the National Cholesterol Education Program definition (3.90% by REF2007, 4.78% by REF2022) and the International Diabetes Federation definition (2.29% by REF2007, 3.10% by REF2022). The prevalence of both abdominal obesity and MS increased over time.Conclusion: The prevalence of abdominal obesity and MS increased in Korean children and adolescents from 2007 to 2020. When analyzed by REF2022, both abdominal obesity and MS showed higher prevalence rates than when using REF2007, indicating that previous reports were underestimated. Follow-up for abdominal obesity and MS using REF2022 is needed.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"170-178"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/b2/jomes-32-2-170.PMC10327689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Constant Association between Low High-Density Lipoprotein Cholesterol and Gastric Cancer Regardless of Site. 低高密度脂蛋白胆固醇与胃癌的持续关联

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-06-30 DOI: 10.7570/jomes22045

Su Youn Nam, Jihyeon Jeong, Seong Woo Jeon

{"title":"Constant Association between Low High-Density Lipoprotein Cholesterol and Gastric Cancer Regardless of Site.","authors":"Su Youn Nam, Jihyeon Jeong, Seong Woo Jeon","doi":"10.7570/jomes22045","DOIUrl":"https://doi.org/10.7570/jomes22045","url":null,"abstract":"Background: Some epidemiologic factors and body mass index (BMI) have site-specific effects on gastric cancer. The site-specific effect of high-density lipoprotein cholesterol (HDL-C) and hyperglycemia on gastric cancer has not been reported.Methods: This study included adults who underwent national gastric cancer screening in 2011 (n=5.49 million). The validation set included gastric cancer patients (n=3,262) and gastric cancer-free persons who underwent health screening (n=14,121) in a single hospital. The site-specific effects of metabolic components and epidemiologic factors on gastric cancer were investigated.Results: Among 5.49 million individuals, 10,417 gastric cancer cases (6,764 non-cardiac gastric cancer [NCGC] and 152 cardiac gastric cancer [CGC]) were detected. BMI was inversely associated with NCGC (P for trend <0.001) but not with CGC. Low HDL-C was associated with both CGC (adjusted odds ratio [aOR], 1.90; 95% confidence interval [CI], 1.34 to 2.71) and NCGC (aOR, 1.41; 95% CI, 1.34 to 1.49). Fasting glucose ≥110 mg/dL was associated with NCGC (aOR, 1.19) and CGC (aOR, 1.50). Men predominance was larger in CGC (aOR, 3.28) than in NCGC (aOR, 1.98). Smoking, alcohol drinking, and family history were associated with NCGC but not with CGC. In the validation set, low HDL-C was associated with CGC (aOR, 2.80) and NCGC (aOR, 2.32). BMI was inversely associated with NCGC (P for trend <0.001), and hyperglycemia was positively associated with both NCGC and CGC.Conclusion: Many epidemiologic factors had site-specific effects on gastric cancer, whereas low HDL-C and hyperglycemia were constantly associated with gastric cancer regardless of the site in two independent sets.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"141-150"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/f4/jomes-32-2-141.PMC10327681.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. 肥胖症的诊断:2022年韩国肥胖症研究学会肥胖症临床实践指南更新。

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-06-30 DOI: 10.7570/jomes23031

Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee

{"title":"Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","authors":"Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee","doi":"10.7570/jomes23031","DOIUrl":"https://doi.org/10.7570/jomes23031","url":null,"abstract":"The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m2 and obesity as a BMI ≥25 kg/m2, based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"121-129"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/42/jomes-32-2-121.PMC10327686.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9766558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. 2022年批准的抗肥胖药物KSSO指南和3期临床试验的承诺:天空和地平线上的抗肥胖药物。

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-06-30 DOI: 10.7570/jomes23032

Eonju Jeon, Ki Young Lee, Kyoung-Kon Kim

{"title":"Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.","authors":"Eonju Jeon, Ki Young Lee, Kyoung-Kon Kim","doi":"10.7570/jomes23032","DOIUrl":"https://doi.org/10.7570/jomes23032","url":null,"abstract":"Obesity is a prevalent global health issue affecting approximately half of the world's population. Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications. While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks. Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs). In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m2 or higher who have not achieved weight reduction through non-pharmacological treatments. Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide. Tirzepatide is awaiting approval, and combination of semaglutide/cagrilintide and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials. Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management. In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics. By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 2","pages":"106-120"},"PeriodicalIF":5.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/d8/jomes-32-2-106.PMC10327684.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9753566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. 肥胖症的诊断:2022年韩国肥胖症研究学会肥胖症临床实践指南更新。

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-06-21 DOI: 10.7570/jome23031

Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee

{"title":"Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","authors":"Ji-Hee Haam, Bom Taeck Kim, Eun Mi Kim, Hyuktae Kwon, Jee-Hyun Kang, Jung Hwan Park, Kyoung-Kon Kim, Sang Youl Rhee, Yang-Hyun Kim, Ki Young Lee","doi":"10.7570/jome23031","DOIUrl":"https://doi.org/10.7570/jome23031","url":null,"abstract":"The prevalence of obesity has consistently increased worldwide, and many obesity-related diseases are emerging as major health problems. Body mass index (BMI) is used to define obesity and is highly correlated with body fat mass. Moreover, obesity-related morbidities increase linearly with the increase in BMI. The Korean Society for the Study of Obesity defined overweight as a BMI ≥23 kg/m2 and obesity as a BMI ≥25 kg/m2, based on a significant increase in obesity-related diseases. A waist circumference of ≥90 cm in men and ≥85 cm in women are defined as abdominal obesity, which is also correlated with obesity-related diseases. These diagnostic criteria are the same as in the previous version; however, the updated guidelines put greater emphasis on the use of morbidity as the basis for obesity and abdominal obesity diagnoses. These new guidelines will help to identify and manage high-risk groups for obesity-related comorbidities among Korean adults.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucose Control in Korean Patients with Type 2 Diabetes Mellitus according to Body Mass Index. 韩国2型糖尿病患者体重指数对血糖控制的影响

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-03-30 DOI: 10.7570/jomes22047

Ye-Lim Shin, Heesoh Yoo, Joo Young Hong, Jooeun Kim, Kyung-do Han, Kyu-Na Lee, Yang-Hyun Kim

{"title":"Glucose Control in Korean Patients with Type 2 Diabetes Mellitus according to Body Mass Index.","authors":"Ye-Lim Shin, Heesoh Yoo, Joo Young Hong, Jooeun Kim, Kyung-do Han, Kyu-Na Lee, Yang-Hyun Kim","doi":"10.7570/jomes22047","DOIUrl":"https://doi.org/10.7570/jomes22047","url":null,"abstract":"Background: The prevalence of type 2 diabetes mellitus has continued to rise. Although many studies have focused on the connection between weight loss and glucose control, only a few studies have investigated the association between body mass index (BMI) and glucose control status. We examined the association between glucose control and obesity.Methods: We analyzed 3,042 participants with diabetes mellitus who were aged ≥19 years when they participated in the 2014 to 2018 Korean National Health and Nutrition Examination Survey. The participants were divided into four groups according to their BMI (<18.5, 18.5-23, 23-25, and ≥25 kg/m2). We used guidelines from the Korean Diabetes Association to compare the glucose control in those groups, with a cross-sectional design, multivariable logistic regression, and glycosylated hemoglobin <6.5% as the reference.Results: Overweight males aged ≥60 years had a high odds ratio (OR) for degraded glucose control (OR, 1.706; 95% confidence interval [CI], 1.151 to 2.527). Among obese females, those in the ≥60 years age group showed an increased OR for uncontrolled diabetes (OR, 1.516; 95% CI, 1.025 to 1.892). Moreover, in females, the OR for uncontrolled diabetes tended to increase as the BMI increased (P=0.017).Conclusion: Obesity is associated with uncontrolled diabetes in female patients with diabetes who are aged ≥60 years. Physicians should closely monitor this group for diabetes control.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"55-63"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/24/jomes-32-1-55.PMC10088554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Rate Responses at Rest, during Exercise and after Exercise Periods in Relation to Adiposity Levels among Young Nigerian Adults. 尼日利亚年轻人在休息时、运动期间和运动后的心率反应与肥胖水平的关系

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-03-30 DOI: 10.7570/jomes22055

Uchechukwu Dimkpa, Robert C Godswill, Peter Okonudo, David Ikwuka

{"title":"Heart Rate Responses at Rest, during Exercise and after Exercise Periods in Relation to Adiposity Levels among Young Nigerian Adults.","authors":"Uchechukwu Dimkpa, Robert C Godswill, Peter Okonudo, David Ikwuka","doi":"10.7570/jomes22055","DOIUrl":"https://doi.org/10.7570/jomes22055","url":null,"abstract":"Background: There is a dearth of comparative studies on heart rate (HR) abnormalities at rest, chronotropic responses during submaximal exercise, and such responses during recovery from submaximal exercise between healthy-weight and overweight/obese young adults.Methods: Eighty healthy young adults (30 men and 50 women) aged 19 to 33 years participated in the present study. A symptom-limited, submaximal, cycle ergometer exercise test of intensity targeted at 60% to 70% of the subject's age-predicted maximum HR was performed. The HR, blood pressure, and minute ventilation were measured at rest and during exercise. Post-exercise, HR was first measured at 1 minute of recovery and then every 2 minutes until the 5th minute.Results: Our results showed significantly higher resting HR (P<0.001), lower percentage HR reserve during exercise (P<0.001), and slower HR recovery after exercise (P<0.05, P<0.01, or P<0.001) in overweight/obese men and women than in the non-overweight/obese controls. The prevalence of high resting HR, submaximal chronotropic incompetence, and blunted HR recovery were more common in the overweight/obese individuals than in the healthy-weight controls. Peak VO2 and ventilatory equivalent for oxygen were associated with resting HR, exercise HR parameters, and post-exercise HR recovery indices in both men and women.Conclusion: High resting HR, submaximal chronotropic incompetence, and blunted HR recovery in overweight/obese individuals in this study may be attributed to poor cardiorespiratory fitness and low respiratory efficiency.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"87-97"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/b3/jomes-32-1-87.PMC10088548.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9643090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. 替西帕肽治疗2型糖尿病和肥胖的有效性和安全性。

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-03-30 DOI: 10.7570/jomes22067

Rachel Sinha, Dimitris Papamargaritis, Jack A Sargeant, Melanie J Davies

{"title":"Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.","authors":"Rachel Sinha, Dimitris Papamargaritis, Jack A Sargeant, Melanie J Davies","doi":"10.7570/jomes22067","DOIUrl":"https://doi.org/10.7570/jomes22067","url":null,"abstract":"The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss. Tirzepatide is the first dual GLP-1/GIP receptor co-agonist which has been approved for treatment of type 2 diabetes mellitus (T2DM) based on the findings from the SURPASS program. The SURPASS trials assessed the safety and efficacy of tirzepatide in people with T2DM, from monotherapy through to insulin add-on in global populations, with another two trials dedicated to Japanese population. Over periods of treatment up to 104 weeks, once weekly tirzepatide 5 to 15 mg reduced glycosylated hemoglobin (1.87% to 3.02%), body weight (5.4 to 12.9 kg) and improved multiple cardiometabolic risk factors (including reduction in liver fat, new-onset macroalbuminuria, blood pressure, and lipids) across the T2DM spectrum. Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine. All tirzepatide doses were well tolerated with similar side-effect profile to the GLP-1 receptor analogues. In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"25-45"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/6e/jomes-32-1-25.PMC10088547.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Weight Loss Prediction after Metabolic and Bariatric Surgery. 代谢和减肥手术后体重下降预测。

IF 5.2

Journal of Obesity & Metabolic Syndrome Pub Date : 2023-03-30 DOI: 10.7570/jomes23008

Ji Yeon Park

{"title":"Weight Loss Prediction after Metabolic and Bariatric Surgery.","authors":"Ji Yeon Park","doi":"10.7570/jomes23008","DOIUrl":"https://doi.org/10.7570/jomes23008","url":null,"abstract":"Metabolic/bariatric surgery is currently the most effective measure to treat morbid obesity and obesity-related comorbidities such as type 2 diabetes. It has proven effective not only in terms of short-term weight loss, but also in maintaining the lower body weight for several decades. Such weight loss improves patient quality of life and extends life expectancy. It is crucial for patients to understand the likely results of a given bariatric procedure so that they can make an informed decision about whether to undergo surgery. The amount of weight loss after metabolic/bariatric surgery is usually the most important outcome of interest to patients considering surgical treatment. It is also the most common primary endpoint for healthcare providers. Patients undergoing surgery want tangible and realistic expectations about how much weight they could lose after surgery, and healthcare professionals need to determine at each follow-up visit after surgery whether patients are on track to reach their weight loss target so they can provide timely intervention to patients with insufficient weight loss or weight regain. Weight loss after metabolic/bariatric surgery is influenced by many clinical variables, including initial body mass index, age, gender, ethnicity, and type of surgery. A well-validated chronological weight loss prediction model would enable patient-centered counseling and goal setting. This review summarizes and compares several publicly available prediction models.","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":"32 1","pages":"46-54"},"PeriodicalIF":5.2,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/58/jomes-32-1-46.PMC10088553.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9289089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2